Utilization, safety, and tolerability of ocrelizumab: data from the providence ocrelizumab registry

Smoot, K; Stuchiner, T; Grote, L; Chen, C; Cohan, S

MULTIPLE SCLEROSIS JOURNAL, 2022; 28 (3_SUPPL): 386